Introduction
============

Chemokines are a group of small (8--14 kDa) cytokines that exert key roles in the regulation of cell migration, proliferation and survival, and that are involved in many biological processes including antigen-presentation and angiogenesis.[@R1]^,^[@R2] Chemokines are divided into four main groups based on their molecular structure and bind to heptahelical G-protein coupled receptors. Diverse stimuli of host or pathogen origin can induce the release of cytokines as well as the expression of chemokine receptors on a wide range of cells, including immunocompetent and hematopoietic cells.[@R3]^,^[@R4] An aberrant chemokine release profile can be observed in many malignancies[@R5]^-^[@R7] as well as in several autoimmune and inflammatory diseases.[@R8]

Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic stem cell diseases. The International Prognostic Scoring System is used for prognostic evaluation of MDS patients, and---based on the percentage of bone marrow blasts, number of cytopenias and karyotype---distinguishes between the four risk groups: low, intermediate-1, intermediate-2 and high.[@R9] Depending on age, the median survival of these patients ranges from 0.3 to 11.8 y. In addition, the WHO classification[@R10] discriminates between different MDS subtypes based on (1) peripheral blood cytopenia, (2) bone marrow dysplasia in one or more of the major myeloid cell lines, (3) the number of blasts in peripheral blood and bone marrow and (4) the appearance of ring sideroblasts. Common features of all MDS subtypes are ineffective hematopoiesis, increased risk of developing acute myeloid leukemia and augmented prevalence of immune deregulation.

The only curative treatment for all types of MDS is allogeneic stem cell transplantation.[@R11] However, abnormalities in the cellular and humoral immune system have been described in MDS patients independent of their subtype, and immunomodulating drugs (e.g., 5-azacitidine and lenalidomide) have therefore been investigated as potential therapies.[@R12]^-^[@R14] Recent studies have also shown that chemokine expression levels are of prognostic value for MDS patients,[@R15]^,^[@R16] yet little is known about the expression pattern of chemokine receptors in MDS. Based on these premises, we wanted to investigate whether T-cell chemokine expression levels differed in healthy individuals as compared with low- and high-risk MDS patients. T cells from MDS patients are usually studied starting from cryopreserved material. Investigating chemokine receptor expression is challenging in this context, since internalization may occur at low temperatures. In the present work, we characterized the expression pattern of chemokine receptors on fresh T cells obtained from peripheral blood samples of an unselected group of MDS patients, focusing on various T-cell subpopulations.

Results
=======

The frequency of total circulating T cells and most T-cell subsets do not differ between MDS patients and healthy individuals
-----------------------------------------------------------------------------------------------------------------------------

The relative numbers of total T cells and various lymphocyte subsets were determined in the peripheral blood of MDS patients and healthy controls ([Table 1](#T1){ref-type="table"}). The abundance of total CD3^+^ T, natural killer (NK) and NKT cells was estimated as the percentage of the total lymphocyte population and did not differ between MDS patients and healthy subjects. The CD4^+^ or CD8^+^ T-cell subsets were determined as the percentage of CD3^+^ cells, and these subsets did not differ between patients and healthy individuals either ([Table 1](#T1){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}).

###### **Table 1.** Characterization of circulating lymphocytes in MDS patients and healthy controls

                      Healthy controls        Low-risk MDS   High-risk MDS                                      
  ------------------- ----------------------- -------------- --------------- ----- -------- ---- ----- -------- ----
  **T-lymphocytes**   CD3^+^                  66             43--82          62    10--85   ns   66    53--92   ns
  **NK**              CD3^-^ CD56^+^CD16^+^   18             6--39           15    3--53    ns   10    2--22    ns
  **NKT**             CD3^+^ CD56^+^CD16^+^   1.7            0--10           1.3   0--19    ns   1.1   0.5--8   ns

  CD4^+^ LYMPHOCYTES                                                                                  
  -------------------------- --------------------- ---- -------- ---- --------- ------ ---- --------- ----
  **Total CD4^+^**           CD3^+^CD4^+^ CD8^-^   68   36--85   69   45--89    ns     57   40--87    ns
  CD4^+^ Naive               CD45RA^+^ CD62L^+^    32   3--51    26   9--62     ns     33   7--51     ns
  CD4^+^ Central Memory      CD45RA^-^ CD62L^+^    34   20--55   28   19--65    ns     29   14--48    ns
  CD4^+^ Effector Memory     CD45RA^-^ CD62L^-^    31   15--76   32   12--54    ns     36   17--64    ns
  CD4^+^ Terminal Effector   CD45RA^+^ CD62L^-^    2    0.4--7   5    0.5--17   0.03   2    0.3--32   ns

  CD8^+^ LYMPHOCYTES                                                                             
  -------------------------- --------------------- ---- -------- ---- -------- ---- ---- ------- ----
  **Total CD8^+^**           CD3^+^CD4^+^ CD8^-^   22   10--51   13   3--44    ns   19   4--41   ns
  CD8^+^ Naive               CD45RA^+^ CD62L^+^    20   4--61    8    2--50    ns   12   4--24   ns
  CD8^+^ Central Memory      CD45RA^-^ CD62L^+^    10   5--58    9    1--35    ns   7    1--41   ns
  CD8^+^ Effector Memory     CD45RA^-^ CD62L^-^    31   11--66   30   13--85   ns   34   6--73   ns
  CD8^+^ Terminal Effector   CD45RA^+^ CD62L^-^    21   7--58    42   4--76    ns   38   6--74   ns

The studies included 18 healthy controls, 22 low-risk and 9 high-risk MDS patients. The percentage of various lymphocyte populations were estimated as follows: (i) total T lymphocytes, NK and NKT cells as the percentage of total lymphocytes; (ii) CD4^+^ and CD8^+^ T cells as the percentage of the total CD3^+^ T cells; and (iii) The CD4^+^ and CD8^+^ T cell subsets as the percentage of total CD4^+^ and CD8^+^ T cells, respectively. All p-values refer to a statistical comparison between high- or low-risk MDS patients and healthy controls.

![**Figure 1.** Lymphocyte subset distribution in the peripheral blood is similar in myelodysplastic syndrome patients and healthy individuals. A-C. Scatter plots show the distribution and median levels of selected T-cell subsets in healthy individuals, low- and high-risk myelodysplastic syndrome (MDS) patients (light gray, dark gray and black symbols, respectively). (**A**) Levels of circulating CD3^+^ cells as percentage of total lymphocytes. (**B**) Levels of circulating CD4^+^ (middle left) and CD8^+^ (middle right) cells as percentage of CD3^+^ cells. (**C**) Levels of circulating CD4^+^ terminal effector cells (logarithmic scale).](onci-2-e23138-g1){#F1}

Thereafter, multiple CD4^+^ and CD8^+^ T-cell subsets were estimated as the percentage of total CD4^+^ and CD8^+^ T cells, respectively. The percentage of CD4^+^ terminal effector cells was significantly increased in low-risk MDS patients as compared with healthy subjects (p = 0.03), whereas all the other CD4^+^ and CD8^+^ T-cell subsets did not differ between our MDS patients and healthy individuals. To conclude, we observed no major differences in the relative abundance of total T cells and various T-cell subsets when comparing our cohort of high- and low-risk MDS patients with healthy people, the only exception being a proportion of CD4^+^ terminal effector cells in low-risk MDS patients ([Fig. 1](#F1){ref-type="fig"}).

Disease-associated alterations in the expression of chemokine receptors by circulating T cells affect different lymphocyte subsets in high- and low-risk MDS patients
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

The T-cell expression of various chemokine receptors was examined in high-risk (n = 9) and low-risk (n = 22) MDS patients, as well as in 18 healthy control individuals. The results for total CD3^+^ T cells and for CD4^+^ and CD8^+^ T-cell subsets are summarized in [Table 2](#T2){ref-type="table"} and illustrated in detail in [Figure 2](#F2){ref-type="fig"}. Both high- and low-risk MDS patients showed increased levels of circulating CD3^+^ CCR3^+^ T cells. However, when the analysis was focused on CD4^+^ and CD8^+^ T-cell subsets separately, only low-risk patients were found to exhibit increased levels of CD3^+^CD8^+^CCR3^+^ cells, whereas for high-risk patients only exhibited an increase in CD3^+^CD4^+^CCR3^+^ cells. Thus, an augmented expression of CCR3 was observed in different T-cell subsets in low-risk and high-risk MDS patients.

###### **Table 2.** Expression of chemokine receptors by CD3^+^, CD4^+^ and CD8^+^ lymphocytes from healthy controls and MDS patients

      Control   Low-risk MDS   High-risk MDS                                                
  --- --------- -------------- --------------- ----- ---------- --------- ----- ----------- ---------
      CCR2      0.1            (0.0--1)        0.2   (0.0--7)   0.02      0.1   (0--0.2)    Ns
      CCR3      0.7            (0.0--1)        1.4   (0.4--4)   \< 0.01   1.5   (0.7--13)   \< 0.01
      CCR4      20             (7--53)         15    (3--38)    Ns        15    (10--25)    Ns
      CCR5      24             (13--52)        28    (10--51)   Ns        32    (16--46)    Ns
      CCR6      27             (8--47)         19    (6--55)    Ns        19    (3--44)     Ns
      CCR7      42             (8--70)         31    (8--71)    Ns        31    (9--49)     Ns
      CXCR3     39             (10--53)        40    (6--60)    Ns        39    (9--72)     Ns
      CXCR4     32             (8--62)         37    (11--63)   Ns        43    (23--58)    Ns
      CX3CR1    8              (4--22)         19    (3--53)    Ns        20    (8--56)     0.03

  CD4^+^                                                                          
  -------- -------- ----- ------------ ----- ---------- ------ ----- ----------- ---------
           CCR2     0.1   (0.0--0.4)   0.1   (0.0--1)   Ns     0.1   (0--0.2)    Ns
           CCR3     0.6   (0.0--1)     0.8   (0.2--5)   Ns     4     (0.4--18)   \< 0.01
           CCR4     23    (3--58)      17    (5--40)    Ns     19    (5--27)     Ns
           CCR5     20    (11--42)     24    (7--47)    Ns     27    (8--48)     Ns
           CCR6     29    (12--52)     24    (10--56)   Ns     27    (18--46)    Ns
           CCR7     47    (10--68)     41    (8--74)    Ns     42    (13--59)    Ns
           CXCR3    36    (18--50)     40    (8--60)    Ns     32    (9--85)     Ns
           CXCR4    36    (9--65)      41    (12--64)   Ns     44    (21--64)    Ns
           CX3CR1   3     (0.8--10)    7     (2--39)    0.03   10    (3--42)     0.03

  CD8^+^                                                                            
  -------- -------- ----- ---------- ----- ----------- --------- ----- ----------- ------
           CCR2     0.1   (0--0.3)   0.2   (0.0--2)    Ns        0.1   (0--0.2)    Ns
           CCR3     0.7   (0--2)     1.4   (0.4--9)    \< 0.01   1.6   (0.5--9)    Ns
           CCR4     13    (2--35)    8     (0.5--50)   0.02      17    (0--32)     Ns
           CCR5     43    (16--73)   48    (24--77)    Ns        58    (27--74)    0.03
           CCR6     4     (1--37)    7     (0.4--58)   Ns        5     (0.8--15)   Ns
           CCR7     26    (2--70)    11    (2--52)     0.03      13    (3--31)     Ns
           CXCR3    47    (23--84)   57    (3--89)     Ns        55    (14--76)    Ns
           CXCR4    28    (7--63)    33    (9--76)     Ns        39    (35--53)    0.04
           CX3CR1   25    (8--69)    62    (9--78)     Ns        46    (7--90)     Ns

The studies included 18 healthy controls, 22 low-risk and 9 high-risk MDS patients. The percentage of various lymphocyte populations were estimated as follows: (i) total CD3^+^ T lymphocytes as the percentage of total lymphocytes; (ii) CD4^+^ and CD8^+^ T cells as the percentage of the total CD3^+^ T cells. All p-values refer to a statistical comparison between high- or low-risk MDS patients and healthy controls.

![**Figure 2.** Chemokine receptor expression on T-cell subsets from myelodysplastic syndrome patients show signs of maturation compared with healthy subjects. A-C. Chemokine receptor expression pattern in healthy individuals (light gray), low-risk myelodysplastic syndrome (MDS) patients (gray) and high-risk MDS patients (black) was compared for the total CD3^+^ population (**A**), the CD4^+^ T-cell subset (**B**) and the CD8^+^ T-cell subset (**C**). Asterisks mark statistically significant differences as compared with control individuals (\*p \< 0.05, \*\*p \< 0.01).](onci-2-e23138-g2){#F2}

We also analyzed the expression of eight other chemokine receptors in T cells from MDS patients and healthy subjects. Among high-risk patients, CX3CR1 expression was altered similarly to that of CCR3, that is, the levels of CD3^+^CX3CR1^+^ cells were significantly increased, an effect stemming from the increase of CD3^+^CD4^+^CX3CR1^+^ cells in the presence of normal levels of CD3^+^CD8^+^CX3CR1^+^ cells. The CD8^+^ T-cell subset of high-risk patients also exhibited an increased expression of CCR5 and CXCR4 ([Table 2](#T2){ref-type="table"} and [Fig. 2](#F2){ref-type="fig"}). On the other hand, low-risk patients showed increased levels CX3CR1^+^ cells in the CD4^+^ T-cell compartment whereas the CD8^+^ subset exhibited decreased levels of both CCR4 and CCR7 ([Table 2](#T2){ref-type="table"} and [Fig. 2](#F2){ref-type="fig"}). Thus, the expression of several chemokine receptors is altered in T cells from MDS patients, but CD4^+^ and CD8^+^ subsets are differentially affected by this phenomenon in patients belonging to different risk IPSS groups.

The CCL20/CCR6 axis is an important regulator of the balance between inflammation and tolerance and is important for the trafficking of effector/memory cell subsets.[@R17]^,^[@R18] Conversely, CXCL12/CXCR4 seems to be involved in the pathogenesis of MDS,[@R19]^,^[@R20] the bone marrow microenvironment contains high levels of CXCL12[@R21] and this chemokine has been shown to be important for the trafficking of T cell subsets this anatomical location.[@R22] For these reasons, we investigated CCR6 and CXCR4 expression on various CD4^+^ and CD8^+^ T-cell subsets of MDS patients and healthy individuals more in detail. Receptor expression was then compared among naive, central memory, effector memory and terminal effector T cells ([Table 3](#T3){ref-type="table"}). In this respect, low-risk patients exhibited decreased CCR6 expression by CD4^+^ terminal effector T cells whereas high-risk patients showed an increased expression of CXCR4 by three lymphocyte subsets, namely CD4^+^ central memory, CD8^+^ central memory as well as CD8^+^ effector memory cells. These observations support the notion that the expression pattern of chemokine receptors by T cells is differentially altered in low-risk and high-risk MDS patients.

###### **Table 3.** Expression of the chemokine receptors CCR6 and CXCR4 on subsets of CD4^+^ and CD8^+^ T lymphocytes from healthy controls and MDS patients

                             Control              Low-risk MDS   High-risk MDS                                             
  -------------------------- -------------------- -------------- --------------- ----- --------- --------- ----- --------- ----
  CD4^+^ Naive               CD45RA^+^ CD62L^+^   4              0.9--8          3     0.5--12   Ns        3     1.9--11   Ns
  CD4^+^ Central memory      CD45RA^-^ CD62L^+^   37             14--52          38    15--58    Ns        40    31--57    Ns
  CD4^+^ Effector memory     CD45RA^-^ CD62L^-^   54             12--75          45    14--79    Ns        49    21--66    Ns
  CD4^+^ Terminal effector   CD45RA^+^ CD62L^-^   5              1.0--29         2     0--24     \< 0.01   3     0.3--12   Ns
  CD8^+^ Naive               CD45RA^+^ CD62L^+^   0.4            0.0--38         0.2   0.0--4    Ns        0.5   0.0--2    Ns
  CD8^+^ Central memory      CD45RA^-^ CD62L^+^   3              1.0--27         5     0.0--25   Ns        5     1.6--11   Ns
  CD8^+^ Effector memory     CD45RA^-^ CD62L^-^   14             1.0--42         15    0.4--87   Ns        14    1.0--41   Ns
  CD8^+^ Terminal effector   CD45RA^+^ CD62L^-^   1.4            0.2--25         0.8   0.0--18   ns        0.5   0.1--10   Ns

  Expression of CXCR4 on T-lymphocyte subsets                                                                        
  --------------------------------------------- -------------------- ---- -------- ---- --------- ---- ---- -------- ---------
  CD4^+^ Naive                                  CD45RA^+^ CD62L^+^   73   55--89   79   28--95    Ns   78   40--93   Ns
  CD4^+^ Central memory                         CD45RA^-^ CD62L^+^   30   15--50   36   9--70     Ns   37   29--64   0.03
  CD4^+^ Effector memory                        CD45RA^-^ CD62L^-^   13   6--49    16   3--51     Ns   24   11--33   Ns
  CD4^+^ Terminal effector                      CD45RA^+^ CD62L^-^   18   5--51    12   1.7--51   Ns   19   5--58    Ns
  CD8^+^ Naive                                  CD45RA^+^ CD62L^+^   65   27--92   64   15--94    Ns   74   50--95   Ns
  CD8^+^ Central memory                         CD45RA^-^ CD62L^+^   34   11--44   38   10--83    Ns   53   25--62   \< 0.01
  CD8^+^ Effector memory                        CD45RA^-^ CD62L^-^   19   5--46    23   2--72     Ns   34   13--76   0.02
  CD8^+^ Terminal effector                      CD45RA^+^ CD62L^-^   22   3--62    26   5--76     Ns   39   5--50    Ns

The studies included 18 healthy controls, 22 low-risk and 9 high-risk MDS patients. The percentage of various lymphocyte subpopulations were estimated as the percentage of total CD4^+^ and CD8^+^ T cells, respectively. All p-values refer to a statistical comparison between high- or low-risk MDS patients and healthy controls.

There was a consistent variation between healthy individuals and patients with regard to the expression of several chemokine receptors ([Table 2](#T2){ref-type="table"} and [Fig. 2](#F2){ref-type="fig"}). We therefore investigated whether we could detect any correlation between chemokine receptor expression by CD4^+^ and CD8^+^ T cells. In the entire cohort of MDS patients, significant correlations were seen for CCR5 (p \< 0.001), CCR7 (p = 0.01), CXCR4 (p = 0.03) and CX3CR1 (p = 0.01). All these correlations but that of CX3CR1 remained significant when low-risk patients were analyzed separately. In healthy individuals, significant correlations were only observed for CCR5 (p = 0.001) and CXCR4 (p = 0.003).

A subset of low-risk MDS patients exhibit high levels of CD8^+^ terminal effector cells
---------------------------------------------------------------------------------------

There was a wide variation in the frequency of various CD4^+^ and CD8~+~ T cell subsets among MDS patients ([Table 1](#T1){ref-type="table"}). Five low-risk patients exhibited CD8^+^ terminal effector cell levels exceeding the variation range of healthy individuals. These patients also showed a decreased CD4/CD8 ratio, as well as decreased portions of the CD8^+^ naïve and central memory subsets, and reduced CD3^+^CXCR4^+^ and CD8^+^CCR7^+^ cells as compared with other low-risk patients (p \< 0.01, p = 0.02, p = 0.03, p = 0.02 and p = 0.01, respectively). There was no significant difference in treatment and clinical parameters between the groups. Thus, a minority of the low-risk patients show an expansion of the terminal effector subset, with chemokine receptor expression in line with normal maturation.

Chemokine receptor expression marginally changes over time in clinically stable patients
----------------------------------------------------------------------------------------

We were able to repeat the analyses described above after 12 months for 10 low-risk patients. Eight of these patients experienced stable disease during this period, as judged by clinical criteria and peripheral blood counts, whereas two patients manifested disease progression. Overall, their T-cell subset levels and T-cell chemokine receptor expression pattern did not vary to consistent extents over time. We also compared these parameters focusing on those eight patients that exhibited a clinically stable disease (median time since diagnosis 42 mo; range 24--120 mo) ([Fig. 3](#F3){ref-type="fig"}). In this setting, we observed decreased levels of circulating CD4^+^CCR4^+^ cells after one year (p = 0.03) whereas there was a trend for increased CD4^+^CCR3^+^ and CD4^+^CCR5^+^ cells (p = 0.05). Thus, low-risk MDS patients with clinically stable disease appear to manifest only minor variations in T-cell subset levels and T-cell chemokine receptor expression.

![**Figure 3.** Low-risk myelodysplastic syndrome patients show minor changes in chemokine receptor expression at one-year follow-up. The T-cell chemokine receptor expression pattern was investigated in eight low-risk, clinically stable myelodysplastic syndrome (MDS) patients at enrollment in the study (1) and after one year (2). p values are reported.](onci-2-e23138-g3){#F3}

T-cell subset distribution differs between the bone marrow and the peripheral blood in low-risk MDS patients
------------------------------------------------------------------------------------------------------------

We obtained bone marrow samples for the analysis of the T-cell populations from five low-risk MDS patients. The frequency of CD3^+^ T cells in the lymphocyte population did not differ between the peripheral blood and the bone marrow, but the abundance of various T-cell subsets did so:

-   Decreased levels of CD4^+^ and increased levels of CD8^+^ T cells were detected in the bone marrow as compared with the peripheral blood (p = 0.02 and p = 0.01). Thus, the CD4^+^:CD8^+^ T-cell ratio differs in these two hematopoietic compartments.

-   Bone marrow CD4^+^ central memory cells were decreased and CD4^+^ terminal effector cells were increased (both p = 0.001), compared with peripheral blood

-   Bone marrow CD8^+^ naïve and central memory cells were decreased (p = 0.02 and p \< 0.01, respectively), compared with peripheral blood.

-   The chemokine receptor profile of bone marrow T cells differed from that of their circulating counterparts and was characterized by (1) increased levels of CD3^+^CCR2^+^ (p = 0.02), CD4^+^CCR2^+^ (p = 0.04), CD8^+^CCR2^+^ (p \< 0.01), CD4^+^CCR3^+^ (p = 0.04) cells; and (2) decreased levels of CD3^+^CCR6^+^ (p = 0.01), CD4^+^CCR6^+^ (p = 0.01), CD3^+^CXCR3^+^ (p = 0.04) and CD8^+^CXCR3^+^ (p = 0.02) cells.

To summarize: (1) there seems to be a selective recruitment of circulating T cells to the bone marrow compartment in low-risk MDS patients; (2) the bone marrow exhibits an increased frequency of CCR2^+^ T cells, bearing a chemokine receptor whose expression is increased in T cells from low-risk MDS patients ([Table 2](#T2){ref-type="table"}); (3) in MDS patients, some circulating T-cell subsets bear decreased levels of CCR6 ([Table 3](#T3){ref-type="table"}), and the bone marrow also contains reduced levels of CCR6^+^ T cells; and (4) the decreased frequency of CXCR3^+^ T cells in the bone marrow of MDS seems not associated with a significantly altered expression of CXCR3 on circulating cells ([Table 2](#T2){ref-type="table"}), suggesting that bone marrow T-cell recruitment is not only dependent on the chemokine receptor repertoire but also on other factors, e.g., local chemokine gradients.

The chemokine receptor expression pattern of CD8^+^ T cells correlates with MDS patient prognosis
-------------------------------------------------------------------------------------------------

We have correlated prognostic parameters and T-cell chemokine receptor expression patterns in our patients. Such prognostic parameters were the IPSS score and the variables that used to estimate this score (bone marrow blast counts and peripheral blood cytopenia). The following observations were made:

-   *CXCR4*. When all MDS patients were included in the analysis, there were significant correlations between the bone marrow blast counts and CXCR4 expression levels in circulating CD8^+^ central memory (p \< 0.01) and effector memory (p \< 0.01) T cells. A correlation between blast counts in the bone marrow and CXCR4 expression by CD8^+^ effector memory cells was also detected when low-risk patients were analyzed separately. Furthermore, we observed significant correlations of patient survival with the levels of circulating CD8^+^CXCR4^+^ T cells (p \< 0.05), as well as with CXCR4 expression by CD4^+^ central memory T cells (p \< 0.05). These observations suggest an association between CXCR4 expression and MDS prognosis.

-   *CCR3.* When all MDS patients were included in the analysis, the levels of circulating CD4^+^CCR3^+^ cells were significantly correlated with the IPSS score. There was no correlation between CCR3 expression and neutrophil counts when the whole patient population was investigated, but among low-risk patients we observed a significant correlation between neutrophil counts and the levels of circulating CD3^+^CCR3^+^ T cells (p \< 0.01).

-   *CCR7.* When including all patients in the analysis, the level of circulating CD8^+^CCR7^+^ T cells inversely correlated with neutrophil counts in the peripheral blood (p = 0.02).

Finally, we investigated whether the expression pattern of chemokine receptors exhibited any correlation with the level of circulating lymphocytes in MDS patients. First, we observed significant correlations between the levels of peripheral blood lymphocytes and the levels of CD8^+^CCR5^+^ T cells, when all MDS patients were included in the analysis (p \< 0.01), as well as when low-risk patients were investigated separately (p \< 0.01); and---in this latter setting---the expression of CXCR4 by CD8^+^ central memory T cells (p = 0.04). In addition, inverse correlations were observed between the lymphocyte levels in the peripheral blood and (1) the levels of CD8^+^CCR7^+^ (p \< 0.01) T cells as well as the CCR3 expression levels of CD4^+^ T cells (p = 0.02) when all MDS patients were included in the analysis; and (2) the abundance of CD8^+^CCR7^+^ cells when low-risk patients were studied separately (p = 0.01).

Discussion
==========

This is the first study to describe altered chemokine receptor expression patterns in T cells from MDS patients. These patients may have autoimmune manifestations, and immune mechanisms seem to be involved in the pathogenesis of the disease, at least for a subgroup of patients. Several T-cell abnormalities have been detected, including alterations in the CD4^+^:CD8^+^ T-cell ratio, skewed T-cell subsets, T~H~17/ regulatory T cells imbalance and clonal expansion of autoreactive cytotoxic T cells.[@R13]^,^[@R14]

Even though MDS patients are heterogeneous, they share fundamental biological and clinical characteristics.[@R10] We investigated unselected patients that were consecutively admitted to our department. This group represents patients requiring specialist consultation from a defined geographical area. Our aim was to investigate whether common immunological characteristics can be detected in such a group of unselected patients.

Our study was based on the analysis of cells prepared immediately after sampling and not on cryopreserved cells. Cryopreserved materials usually include a minor cell population of necrotic/apoptotic cells even when optimal techniques for preservation and thawing are applied.[@R23]^,^[@R24] In addition, chemokine receptors may be internalized during cryopreservation. Our methodological approach was chosen to ensure (1) maximal cell viability and (2) a receptor expression pattern maximally reflecting the in vivo situation.

We investigated the chemokine receptor expression pattern in defined T-cell subsets. CD3^+^ T lymphocytes are divided into the major helper CD4^+^CD8^-^ and cytotoxic CD8^+^CD4^-^ cell subsets, which can be further subdivided into naïve (CD62L^+^CD45RA^+^), central memory (CD62L^+^CD45RA^-^), effector memory (CD62L^-^CD45RA^-^) and terminal effector memory (CD62L^-^CD45RA^+^) T cells.[@R25]^,^[@R26] All these subsets can be detected in MDS patients.[@R27] Other studies have used CCR7 and not CD62L to define T-cell subsets,[@R25] but since the main focus of our study were chemokine receptors, we decided not to use this marker to define cell subpopulations. Our findings in MDS patients were compared with those obtained in a group of matched healthy individuals ([Table 2](#T2){ref-type="table"}). Zou et al.[@R27] have previously described a reduction in CD4^+^ and CD8^+^ naive T cells and an increase in the abundance of effector memory and terminal effector subsets in MDS patients. We observed similar trends, in particular for CD8^+^ T cells; although they did not reach statistical significance. This discrepancy may stem from the fact that the average age of our patients was comparatively higher, as Zou et al. described that these differences were most clearly seen among young patients.[@R27]

CCR7 is generally lost when T cells are activated to become terminal effector/effector memory cells.[@R28] CCR5 and CCR3/CCR4 expression are associated with T~H~1 and T~H~2 polarization, respectively.[@R26] CX3CR1 is specifically expressed on mature cells with high cytotoxic capacity, regardless of lineage.[@R29] Chemokine receptor expression profiles can thus be used to define functionally distinct T-cell subsets.[@R26] Our data indicating an increased T-cell expression of CCR3/CCR5/CX3CR1 and decreased expression of CCR7 (see [Table 2](#T2){ref-type="table"}) suggest that T cells from MDS patients have a more mature chemokine receptor profile. This is also consistent with previous studies describing increased levels of terminal effector cells in MDS patients.[@R27]^,^[@R30] Furthermore, high CCL5 serum levels have been reported in low-risk individuals affected by low-risk MDS[@R31] and have been associated with prolonged patient survival.[@R15] CCL5 is a ligand both for CCR3 and CCR5, which were increased in CD8^+^ T cells from low- and high-risk MDS patients, respectively. This altered receptor expression may hence contribute to the prognostic impact of circulating CCL5 levels. Finally, the ligands for CCR4 are CCL17 and CCL22, which can be released by normal dendritic cells as well as by myeloid leukemic blasts and leukemia-derived dendritic cells.[@R32]^,^[@R33] Decreased CCR4 expression in low-risk MDS patients may hence inhibit the migration of T cells in the direction of CCL17/CCL22-producing cells.

There seems to be a similar variation in the expression of several chemokine receptors in CD4^+^ and CD8^+^ T cells ([Fig. 2](#F2){ref-type="fig"}). This was further confirmed by correlation analyses. These observations are consistent with the hypothesis that similar mechanisms regulate chemokine receptor expression in these two T-cell subsets. Still, the differences between patients and control individuals allowed statistical significance to be reached only for certain receptors and/or patient sub-groups.

A small minority of our low-risk patients received cytokine treatment ([Table 4](#T4){ref-type="table"}), which seemed to have only a minor influence on T-cell populations. Moreover, a subset of our patients was examined initially as well as after a one-year delay. The majority of these individuals had clinically stable disease, and most of them had also had stable disease for a relatively long time before the first sampling. Our results demonstrate that immunological alterations may develop over time even though patients are clinically stable.

###### **Table 4.** Patients included in the study, with patient and disease characteristics, treatment received and follow-up time in months

  \#   Gender   Age^1^   Diagnosis^2^   WHO class^3^   Cytopenia(s)^4^   Cytogenetics^5^                                      Treatment^6^   Follow-up time^7^
  ---- -------- -------- -------------- -------------- ----------------- ---------------------------------------------------- -------------- -------------------
  1    M        63       2002           RCMD           A, T              NA                                                   BS             18.1\*
  2    M        70       2009           RCMD           A, N, T           NA                                                   BS             4.5\*
  3    F        89       2005           RARS           A                 NA                                                   BS             33.0
  4    F        84       2000           RARS           A                 NA                                                   BS (E)         33.2
  5    M        88       2009           RCMD           A, N, T           NA                                                   BS (E+G)       7.6\*
  6    M        83       2009           RCMD           A                 46 XY                                                E+G            12.8\*
  7    M        85       2007           RCMD           A, T              45 XY, del(11)(q23) (2011)                           BS             34.1
  8    F        83       2008           RCMD           A, N              NA                                                   G (E+G)        19.2\*
  9    M        68       2009           RCMD           A                 47XY+9\[15\]/47,idem,der (16)(1;16)(q12;q11)\[18\]   BS             4.1\*
  10   M        71       2010           RCMD           A                 46 XY                                                BS             30.7
  11   M        71       2008           RCMD           A, T              46 XY                                                BS (E)         29.3
  12   F        85       2000           RARS           A                 NA                                                   E+G            29.0
  13   M        81       2008           RARS           A                 NA                                                   BS (E)         18.5\*
  14   M        58       2009           RCMD           A                 46 XY                                                E (E+G+A)      33.4
  15   M        67       2010           RCMD           N                 46 XY,t(3;6) (q26;q25)\[27\] (2011)                  BS             21.0
  16   M        85       2011           RCMD           A                 NA                                                   BS             5.0\*
  17   M        73       2000           RARS           A                 NA                                                   BS             19.9
  18   M        93       2011           RCMD-RS        A                 NA                                                   E              1.3
  19   F        73       2012           RAEB-1         N, T              46XX                                                 BS             1.3
  20   F        85       2012           RCMD           A                 NA                                                   BS             0.8
  21   M        73       2011           RCMD           NT                46XY                                                 BS             0.6
  22   M        84       2012           RCMD           A                 46XY                                                 BS             0.6
  23   M        80       2011           RCMD           A, N, T           46 XY                                                BS             Only BM
  24   M        65       2007           RARS           A                 46 XY                                                E+G            Only BM

  HIGH RISK                                                                                                                                                
  ----------- --- ---- ------ -------- --------- -------------------------------------------------------------------------------------------- ------------ --------
  25          M   55   2009   RAEB-2   A, N      46 XY                                                                                        BS(ASCT)     3.0\*
  26          F   57   2010   RAEB-2   A, N, T   46,XX,del(5)(q15q33)\[9\]/46,idem,add(17)(p13),-22+mar\[11\]                                 BS           0.5\*
  27          F   68   2009   RAEB-2   A, N, T   46,XX,del(12)(p11)                                                                           BS (A)       18.8\*
  28          M   66   2010   RAEB-2   A, N, T   46 XY                                                                                        BS (A)       30.7
  29          M   61   2010   RAEB-2   A, T      44--45 XY der(3)t(1;3)(p32;q27)-5del(6)(p23),-7,add(14)(p11),+add(14)(p11),der(18)\[cp20\]   A            4.2\*
  30          M   69   2008   RAEB-1   A, N, T   46,XY,del(12)(p12)\[3\]/46,XY\[17\]                                                          A (G)        21.1
  31          M   66   2011   RAEB-2   A, N, T   46 XY                                                                                        BS(A,ASCT)   19.6
  32          M   71   2012   RAEB-2   A, N, T   47 XY +8 \[10\]                                                                              A            1.3
  33          M   78   2011   RAEB-2   A, N      47 XY +11 \[2\]                                                                              BS           0.8

^1^ Age at first sample,^2^ Year diagnosed with MDS,^3^ RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RAEB-1, refractory anemia with excess blasts-1; RAEB-2, refractory anemia with excess blasts-2, ^4^A, anemia; n, neutropenia; t, thrombocytopenia,^5^ NA, not acquired, ^6^Treatment after sample in parentheses; BS, best supportive care including transfusions if needed; E, erythropoetin; G, G-CSF; A = azacitidine,^7^ Follow-up in months since first sample, BM, bone marrow \*Patients 1, 6, 8 and 13 dead from unrelated disease, 2, 9 and 26 dead from other cancer, 5 and 16 dead from infection, 25 dead from GVHD, 27 and 29 dead from AML.

We characterized T-cell subsets in the bone marrow, and for these experiments we used cryopreserved material. Cryopreservation and thawing may cause the internalization of membrane molecules and can also provoke a minor decrease in cell viability.[@R23]^,^[@R24] However, the differences between our observations in the peripheral blood and bone marrow cannot be explained by a *general* effect induced by cryopreservation/thawing on bone marrow cells, because (1) when comparing relative values we observed an altered CD4^+^:CD8^+^ T-cell ratio, (2) we did not detect any increase in the double negative T-cell subset (i.e., effector memory cells) and (3) there was a selective increase in the expression of specific chemokine receptors. Although we emphasize that these results should be interpreted with care, in our opinion the differences that we observed are most likely due to true differences between circulating and bone marrow T-cell populations. Altered T-cell characteristics caused by several distinct, subset-specific cryopreservation/thawing-induced alterations seem less likely.

Our high-risk MDS patients showed increased CXCR4 expression in mature CD8^+^ T-cell subsets as compared with control individuals. Increased CXCR4 expression was also associated with prolonged survival in high- and low-risk patients, even though CXCR4 expression was not significantly increased among low-risk patients in general ([Table 2](#T2){ref-type="table"}). CXCR4 is normally expressed at high levels on naïve T-cells. This was also true in our high-risk MDS patients, but, in contrast to healthy individuals, these high-risk patients showed relatively high CXCR4 expression levels also in more-mature T-cell subsets ([Table 3](#T3){ref-type="table"}). CXCR4 binds the homeostatic ligand CXCL12, which is released by normal bone marrow stromal cells.[@R34] Hence, the high expression levels of CXCR4 on mature cells from high-risk patients may suggest an abnormal maturation of effector cells, resulting in an increased homing potential to the bone marrow. This is further supported by the detection of increased CXCL12 levels in the bone marrow and plasma of MDS patients.[@R21] Our study thereby suggests that the CXCL12/CXCR4 system has a dual function in human MDS patients: not only is CXCR4 expressed by CD34^+^ bone marrow cells in MDS patients and is important for survival and migration of these cells, as previously shown,[@R19]^,^[@R22] but also CXCR4/CXCL12 is important for the immunoregulation and the recruitment of immunocompetent cells to the bone marrow.

To conclude, the chemokine receptor expression pattern on circulating T cells from MDS patients suggests a dominance of mature T cells as defined by the expression of CD45RA and CD62L. Our results as well as previous studies have demonstrated that there is a wide variation in the levels of circulating T-cell subsets in both MDS patients and healthy individuals, exhibiting a considerable overlap.[@R27]^,^[@R30] The maturation of T cells in MDS patients does not seem to differ from that seen in normal activated lymphocytes, with the exception of increased CXCR4 levels, as observed in mature CD8^+^ T cell subsets of high-risk MDS patients.[@R26]^,^[@R34] Targeting chemokine receptors with monoclonal antibodies or specific inhibitors may affect T-cell trafficking and thereby the interactions between immunocompetent and hematopoietic cells in the bone marrow of MDS patients.

Materials and Methods
=====================

Patients
--------

The studies were approved by the regional ethical committee, REK Vest, REK number 3.2008.409. Patients constitute an unselected group of consecutive individuals diagnosed at our department, i.e., they represent the large majority of patients diagnosed with MDS from a defined geographic area. Patients with IPSS group low and intermediate-1 were considered as low-risk patients (n = 22; median age 82, range 58--93) and patients in intermediate-2 and high were defined as high-risk patients (n = 9; median age 66, range 56--75). For two additional low-risk patients, we were able to analyze bone marrow samples, but not peripheral blood samples. Data on these patients are not presented in the text, but included in [Table 4](#T4){ref-type="table"}. Only a minority of patients received erythropoietin and/or G-CSF at the time of sampling, but nearly half of the low-risk patients required such treatment later on.

The WHO MDS subtypes were represented as follows: refractory anemia with ringed sideroblasts (RARS; n = 5, 16%), refractory cytopenia with multilineage dysplasia (RCMD; n = 15, 48%), RCMD with ring sideroblasts (RMCD-RS; n = 1, 3%), refractory anemia with excess (5--9%) of blasts (RAEB-1; n = 2, 6%), refractory anemia with excess (10--19%) of blasts (RAEB-2; n = 8, 26%). In our study we defined high-risk MDS as WHO class RAEB-1 with disease progression within 6 months and WHO class RAEB-2. All other patients are referred to as low-risk MDS. Median follow-up time from first sampling was 78.7 weeks. For patients 23, 24, we had only bone marrow samples, and do not present follow up data other than that they were both alive at the end of follow-up for the rest of the cohort. Control samples were obtained from healthy volunteers (n = 18, median age 58 y with range 40--83 y).

Cytofluorometric analyses of chemokine receptors on T cells
-----------------------------------------------------------

Blood samples from MDS patients were acquired after written informed consent. Blood collected in EDTA was subject to red cell lysis using Pharmlyse (BD PharMingen) following the manufacturer's instructions. To optimize chemokine receptor expression, samples were kept at room temperature until staining.[@R35] We also analyzed bone marrow (BM) samples from 13 patients. BM was obtained from the posterior iliac crest and BM mononuclear cells (MNCs) were isolated by Ficoll-Hypaque (Nycomed) gradient centrifugation and cryopreserved. For analysis, the cells were thawed and resuspended in StemSpan medium (StemCell Technologies, Inc.), and kept at room temperature.

Approximately 0.5 × 10^6^ cells were added to cytofluorometry tubes containing the antibodies corresponding to five different panels. Antibodies against the following targets were used (conjugated fluorochrome is indicated): CD3 (Pacific Orange, UCHT1, \#CD0330 and APC-Cy7, SK7, \#557832), CD4 (FITC, SK3, \#345768), CD8 (Pacific Blue, RPA-T8, \#558207), CD45RA (PE-Cy7, HI100, \#560675), CD56 (PE, B159, \#555516), CD62L (FITC, DREG-56, \#555543), CCR3 (PE, 5E8, \#558165), CCR4 (PE, 1G1, \#551120), CCR4 (PerCP-Cy5.5, 1G1, \#560726), CCR5 (PE-Cy7, 2D7/CCR5, \#557752), CCR6 (PerCP-Cy5.5, CCR6, \#560467), CCR7 (FITC, 3D12, \#560548), CXCR3 (AlexaFluor^®^488, 1C6/CXCR3, \#558047), CXCR4 (APC, 12G5,\#555976), CX3CR1 (FITC, 2A9--1, \#341606). All antibodies were mouse anti-human, except for anti-CCR7 and anti-CX3CR1 antibodies, which were rat anti-human. Anti-CD3 antibodies were purchased from Invitrogen, (Life Technologies Ltd), CX3CR1 from BioLegend and all other from BD Biosciences. Staining volume was 100 µL, and samples were incubated for 15 min on a shaker, in the dark, at room temperature. Cells were then washed twice with PBS, resuspended in 0,5% bovine serum albumin (BSA), and kept on ice until cytofluorometric analysis. Single stained beads (BD Biosciences) were used for compensation. The samples were analyzed on the same day using a FACSCanto II cytometer (BD Biosciences). An average of approximately 20,000 CD3^+^ cells were analyzed per antibody panel per low-risk patient, and approximately 47, 000 CD3^+^ cells per high-risk patient. Compensation and data analysis were performed by means of the FlowJo 7.6 software (TreeStar Inc.). After setting the compensation, the lymphocyte gate was set by light scatter properties. Cells were then gated on CD3 positivity and CD8 positive and negative gates were set strictly. In one panel, gates were set by displaying CD4 against CD8, hence CCR2-CCR4 represent values in the CD4^+^CD8^-^ and CD8^+^CD4^-^ populations rather than in CD8^+^ or CD8^-^ cells. In some figures, the CD8^-^ population may be referred to as CD4^+^, for the sake of simplicity. Only the CCR2-CCR4 values are gated using a CD4 antibody. CD3^+^CD8^+^ and CD3^+^CD8^-^ T-cell subset analysis was based on the expression of CD45RA and CD62L. Only CCR6 and CXCR4 expression were analyzed in these subsets. For chemokine receptors, the best cut point was found by looking at several subpopulations for shifts and to identify subsets with similar autofluorescence as negative controls. Each gate was adjusted for the chosen subpopulation separately, based on observed shifts. The gating strategy is shown in [Figure 4](#F4){ref-type="fig"}.

![**Figure 4.** Gating strategy. The lymphocyte populations were identified by light scatter properties (side and forward scatter, upper left). T cells were then identified using CD3 expression (middle left), and CCR2-CCR4 expression was analyzed on cells gated on CD4 and CD8 expression (lower left), while CCR5--7, CXCR2--4 and CX3CR1 expression was evaluated upon CD8 gating (middle). T-cell subsets were gated using CD45RA and CD62L on CD8-stained cells (middle right), and these cells were also examined for CCR6 and CXCR4 expression. The gates for detectable chemokine receptor expression were set manually for each individual, and the layover of healthy subject (outline) over MDS patient (gray) is only illustrative. Examples are shown for CCR7 and CCR3 (top and bottom right, respectively).](onci-2-e23138-g4){#F4}

Statistical analyses
--------------------

Mann-Whitney non-parametric tests were used when comparing subset proportions and chemokine receptor expression between patients and healthy individuals. Wilcoxon Signed Ranks tests were used when comparing paired samples. Spearman correlation was applied to detect correlations between chemokine expression and clinical parameters. p values \< 0.05 were considered statistically significant. Statistical analyses were done using IBM SPSS 19.0 (IBM).
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